Sign Up for Updates

Complete this form to receive future updates about CABLIVI and aTTP.

*Required field.

First name*

Last name*

Email*

Phone*

Practice/Institution name

Office address

City

State

ZIP

I am a*

Specialty*

I prefer to be contacted via*:*

aTTP=acquired thrombotic thrombocytopenic purpura.

Global-Advisory-Board-invite

By checking this box, I agree that Sanofi Genzyme Rare Blood Disorders and its agents [such as third-party business partners] can contact me by mail, e-mail, fax and/or telephone, including calls and text messages, and send me information about rare blood disorders and relevant Sanofi Genzyme products, promotions, services and research studies, ask my opinion about such information and topics, including through market research and disease-related surveys, and share the information I provide with one another to perform these activities, and to de-identify it for use in performing research, education, business analytics, marketing studies, and other commercial purposes. Text messaging fees may apply. Your information will not be sold to any third party but may be provided to regulatory authorities if required. You may opt out of continued receipt or such communications at any time by unsubscribing.*

You may have certain rights under applicable data privacy laws regarding your personal information, including the right to access your personal information held by Sanofi Genzyme. For further information regarding these rights, please reference our Global Privacy Policy.

I accept Sanofi’s Terms and Conditions and Privacy Policy

By checking this box, you confirm that you are a US physician. You also acknowledge that you understand that the information you provide may be used by Sanofi Genzyme, their affiliates, and the business service companies working with Sanofi Genzyme to provide you with additional communications and to develop products and services which may include market research.

Sanofi Genzyme respects interests in keeping your information private and will not sell or rent your information to any third parties or outside mailing lists. For more information on our use of information, see our Privacy Policy.

IMPORTANT SAFETY INFORMATION AND INDICATIONS

CONTRAINDICATIONS:

CABLIVI is contraindicated in patients with a previous severe hypersensitivity reaction to caplacizumab-yhdp or to any of its excipients. Hypersensitivity reactions have included urticaria.

WARNINGS AND PRECAUTIONS:

Bleeding Risk:

CABLIVI increases the risk of bleeding. In clinical studies, severe bleeding adverse reactions of epistaxis, gingival bleeding, upper gastrointestinal hemorrhage, and metrorrhagia were each reported in 1% of subjects. Overall, bleeding events occurred in approximately 58% of patients on CABLIVI versus 43% of patients on placebo. The risk of bleeding is increased, in patients with underlying coagulopathies and concomitant use of CABLIVI with drugs affecting hemostasis.
If clinically significant bleeding occurs, interrupt use of CABLIVI. Von Willebrand factor concentrate may be administered to rapidly correct hemostasis. If CABLIVI is restarted, monitor closely for signs of bleeding.
Withhold CABLIVI for 7 days prior to elective surgery, dental procedures or other invasive interventions. If emergency surgery is needed, the use of von Willebrand factor concentrate may be considered to correct hemostasis. After the risk of surgical bleeding has resolved, and CABLIVI is resumed, monitor closely for signs of bleeding.

ADVERSE REACTIONS:

The most common adverse reactions (>15% of patients) were epistaxis (29%), headache (21%) and gingival bleeding (16%).

CONCOMITANT USE OF ANTICOAGULANTS:

Concomitant use of CABLIVI with any anticoagulant may increase the risk of bleeding. Assess and monitor closely for bleeding with concomitant use.

PREGNANCY:

There are no available data on CABLIVI use in pregnant women to inform a drug associated risk of major birth defects and miscarriage.

Fetal/neonatal adverse reactions: CABLIVI may increase the risk of bleeding in the fetus and neonate. Monitor neonates for bleeding.
Maternal adverse reactions: All patients receiving CABLIVI, including pregnant women, are at risk for bleeding. Pregnant women receiving CABLIVI should be carefully monitored for evidence of excessive bleeding.

INDICATIONS:

CABLIVI (caplacizumab-yhdp) is indicated for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.

Please see full Prescribing Information
Instructions for Use
Sharps Medical Waste Disposal (PDF)
Click here to learn more about Sanofi's commitment to fighting counterfeit drugs.

Back to the top